

Electronic Information Disclosure Statement

RECEIVED
FEB 06 2003
TECH CENTER 1600

OFFICE
FEB 04 2003

Anti-inflammatory indole derivative

Application: 
09/889515

Confirmation: 5223

Applicant(s): Alan Fauli

Docket Number: ASZD-P01-471






Group Art Unit: 1626

Examiner: ~~Wright, Sonya N.~~ *Robert Shiao*

search string: (3557142 or 3776923 or 3997557 or 4384994 or 4529724 or 4608384 or 4675332 or 4721725 or 4751231 or 4965369 or 5081145 or 5190968 or 5254563 or 5272145 or 5273980 or 5288743 or 5290798 or 5308850 or 5389650 or 5399699 or 5482960 or 5604253 or 5639780 or 5684032 or 5852046 or 5877199 or 5955492 or 6184235).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
<i>JS</i>	P01	3557142	1971-01-19		Bell		
	P02	3776923	1973-12-04		Remers et al.		
	P03	3997557	1976-12-14		Helsley et al.		
	P04	4384994	1983-05-24		Verber et al.		
<i>JS</i>	P05	4529724	1985-07-16		Ho		

PO: 

TECH CENTER 1600/2900

RECEIVED

(Remarks are not for responding to an office action.)

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent,

information as defined in [17]. If $\mathcal{I}(\mathbf{X}) = \mathbf{X}$, we say that \mathbf{X} is a *perfect* information as defined in [17]. If $\mathcal{I}(\mathbf{X}) \neq \mathbf{X}$, we say that \mathbf{X} is a *partial* information as defined in [17]. If $\mathcal{I}(\mathbf{X}) = \emptyset$, we say that \mathbf{X} is a *trivial* information as defined in [17]. If $\mathcal{I}(\mathbf{X}) \neq \emptyset$, we say that \mathbf{X} is a *non-trivial* information as defined in [17]. If $\mathcal{I}(\mathbf{X}) = \mathbf{X}$, we say that \mathbf{X} is a *perfect* information as defined in [17]. If $\mathcal{I}(\mathbf{X}) \neq \mathbf{X}$, we say that \mathbf{X} is a *partial* information as defined in [17]. If $\mathcal{I}(\mathbf{X}) = \emptyset$, we say that \mathbf{X} is a *trivial* information as defined in [17]. If $\mathcal{I}(\mathbf{X}) \neq \emptyset$, we say that \mathbf{X} is a *non-trivial* information as defined in [17].

appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be applied against the claims of the present application.

FEB 9 4 2003

Signature

RECEIVED
FEB 06 2003
TECH CENTER 1600/2900

Examiner Name	Date
<i>Robb</i>	<i>6/4/04</i>

P-PTO SB 08

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Use several sheets if necessary.

Docket Number (Optional)

AS/D-P01-471

Application Number

09 889,515

Applicant

Faull et al.

Filing Date

October 10, 2001

Group Art Unit

1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED
FEB 07 2003
TECH-CENTER 1800/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
12	AA DE 298 913 A5	3/1992	Germany				X
	AB EP 0 189 690	8/6/86	EPO				
	AC EP 0 419 049 A1	3/27/91	EPO				
	AD EP 0 480 659 A2	4/15/92	EPO				
	AE EP 0 535 923 A1	4/7/93	EPO				
	AF EP 0 535 924 A1	4/7/93	EPO				
	AG EP 0 535 925 A1	4/7/93	EPO				
	AH EP 0 535 926 A1	4/7/93	EPO				
	AI EP 0 639 573 A1	2/22/95	EPO			Abstract	
	AJ EP 0 822 185	2.4.98	EPO				
13	AK EP 0 275 667	7/27/98	EPO				
	AL FR 2 565 981	12/20/85	France			Abstract	
	AM JP 63284177	11/21/88	Japan			Abstract	
	AN JP 4273857	9/30/92	Japan			Abstract	
	AO WO 86 00896	2/13/86	WIPO				
	AP WO 92 04343	3/19/92	WIPO				
	AQ WO 93 16069	8/19/93	WIPO				
	AR WO 93 20078	10/14/93	WIPO				
	AS WO 94 14434	7/7/94	WIPO				
			WIPO				

Form PTO SB 08 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Docket Number (Optional) AS/D-P01-471		Application Number 09 889,515	
Applicant Faull et al.				Filing Date October 10, 2001		Group Art Unit 1626	
13	AW	WO 97 13615	4/10/97	WIPO			
	AX	WO 97 30704	8/28/97	WIPO			
	AY	WO 97 35572	10/2/97	WIPO			
13	AZ	WO 98 06703	2/19/98	WIPO			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

13	BA	Berman, J.W. et al. Localization of Monocyte Chemoattractant Peptide-1 Expression in the Central Nervous System in Experimental Autoimmune Encephalomyelitis and Trauma in the Rat. <i>J. Immunol.</i> 156, 3017-3023 (1996).
	BB	Bobosik, V. & Krutosikova, A. Synthesis of N-Phenylsulfonyl Protected Furo[3,2-b]Pyrroles. <i>Collect. Czech. Chem. Commun.</i> 59, 499-502 (1994).
	BC	Dandarova, M. ¹³ C NMR Spectra of Some Substituted Furo[3,2-b]pyrroles. <i>Magnetic Resonance Chem.</i> 28, 830-831 (1990).
	BD	Deleuran, M. et al. Localization of monocyte chemotactic and activating factor (MCAF/MCP 1) in psoriasis. <i>J. Dermatological Sci.</i> 13, 228-236 (1996).
	BE	Grimm, M.C. et al. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. <i>J. Leukocyte Biol.</i> 59, 804-812 (June 1996).
	BF	Harrison, C.-A. et al. Cyclopenta [b] indoles. Part 2. Model studies towards the tremorgenic mycotoxins. <i>J. Chem. Soc. Perkin Trans.</i> 1131-1136 (1995).
	BG	Hartman, G.D. & Halczenko, W. The Synthesis of 5-Alkylaminomethylthieno[2,3-b]pyrrole-5-sulfonamides. <i>Heterocycles</i> 29, 1943-1949 (1989).
	BH	Jones, M.L. et al. Potential Role of Monocyte Chemoattractant Protein 1-JE in Monocyte/Macrophage-Dependent IgA Immune Complex Alveolitis in the Rat. <i>J. Immunol.</i> 149, 2147-2154 (15 Sept. 1992).
	BI	Kataoka, K. et al. Homopiperazines as cell migration inhibitors. <i>Chemical Abstracts</i> . Columbus Ohio, US 123, 667 (2 October 1995).
	BJ	Koch, A.E. et al. Enhanced Production of Monocyte Chemoattractant Protein-1 Rheumatoid Arthritis. <i>J. Clin. Invest.</i> 90, 772-779 (Sept. 1992).
	BK	Korobchenko, L.V. et al. Synthesis and antiviral activity of pyrrolicarboxylic acids and their derivatives. <i>Chemical Abstracts</i> . Columbus, Ohio. Access Number: 119 62465 (1999).
	BL	Krutosikova, A. & Dandarova, M. Substituted Vinyl Azides in Synthesis of Furo[3,2-b:4,5-b']-Dipyrroles and Pyrrolo[2',3':4,5]Furo[3,2-c]Pyridines. <i>Heterocycles</i> 37, 1695-1700 (1994).
13	BM	Krutosikova, A. & Dandarova, M. Reactions of Methyl 2-Formylfuro[3,2-b]pyrrole-5-carboxylates. <i>Chem. Papers</i> 50, 72-76 (1996).

77 (18) (101, 1995)

Form PTO SB 08

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)

AS/D-P01-471

Application Number

09 889.515

Applicant

Faull et al.

Filing Date

October 10, 2001

Group Art Unit

1626

BO	Krutosikova, A. et al. Condensed O-, N-Heterocycles by the Transformation of Azidoacrylates. <i>Chemical Monthly</i> 123, 807-815 (1992).
BP	Krutosikova, A. et al. Derivatives of Furo[3,2-b]Pyrrole. <i>Collect. Czech. Chem. Commun.</i> 59, 473-481 (1994).
BQ	Krutosikova, A. et al. Substituted Vinyl Azides in the Synthesis of Condensed Nitrogen Heterocycles. <i>Chem. Papers</i> 48, 268-273 (1994).
BR	Krutosikova, A. et al. Synthesis and Reactions of Furo[3,2-b]Pyrrole Type Aldehydes. <i>Collect. Czech. Chem. Commun.</i> 58, 2139-2149 (1993).
BS	Krutosikova, A. et al. Synthesis and Reactions of Furo[2,3-b]pyrroles. <i>Molecules</i> 2, 69-79 (1997).
BT	Murakami, Y. et al. Direct Regioselective Vinylation of Indoles Using Palladium(II) Chloride. <i>Heterocycles</i> 22, 1493-1496 (1984).
BU	Rosenmund, P. et al. Decarboxylations of Some 1-Alkyl-2-carboxy-3-indolacetic Acids and Synthesis of a 5-Thiocyanato-2,3-dihydroindole. <i>Chem. Ber.</i> 108, 3538-3542 (1975). - Abstract only.
BV	Troschutz, R. & Hoffmann, A. Synthesis of Substituted 3-Amino-4-cyano-1-oxo-1,2,5,10-tetrahydroazepino[3,4-b]indoles. <i>J. Heterocyclic Chem.</i> 34, 1431 (1997).
BW	Yokoyama, Y. et al. Palladium-Catalyzed Cross-Coupling Reaction: Direct Allylation of Aryl Bromides with Allyl Acetate. <i>Tetrahedron Letters</i> 26, 6457-6460 (1985).
BX	Yokoyama, Y. et al. New Synthetic Method for Dehydrotryptophan Derivatives. Synthesis Studies on Indoles and Related Compounds. XXIV. <i>Chem. Pharm. Bull.</i> 42, 832-838 (1994).
EXAMINER	DATE CONSIDERED
EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE